Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.